Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022
November 07, 2022 16:05 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
September 22, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022
September 12, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patientsResponses achieved in patients with 3...
Onconova Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 01, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022 16:05 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022
August 04, 2022 16:05 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Announces Key Management Promotions
June 13, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer Dr. Adar Makovski Silverstein promoted to Senior Director and Head of Corporate Development NEWTOWN, Pa., June 13, 2022 ...
Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory and Improved Safety Profile in Preclinical Models
May 26, 2022 17:10 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022 16:05 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter Financial Results on May 11, 2022
May 04, 2022 16:05 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...